Business Context and Reporting Period
This Form 6-K was filed by NLS Pharmaceutics Ltd., not Newcelx Ltd., for the month of March 2024 (Report No. 2). It was signed on March 13, 2024. The filing reports amendments to the company’s Swiss articles of association following a share capital increase.
Capitalization and Other Key Metrics
- The company increased share capital by CHF 77,829.38.
- The increase resulted from the issuance of 3,891,469 fully paid-in registered shares with a nominal value of CHF 0.02 per share.
- Total outstanding share capital increased to CHF 791,264.98, divided into 39,563,249 registered shares.
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating financial metrics.
Material Changes Versus the Prior Comparable Period
The filing does not present comparative financial information. The disclosed material change is the increase in issued share capital and outstanding shares pursuant to a board resolution dated January 17, 2024.
Guidance, Outlook, Risks, and Unusual Items
No guidance, operating outlook, management discussion, risk update, contingencies, or unusual operating items are disclosed. The share issuance may affect ownership percentages and potential dilution for existing shareholders, although the filing does not state the issuance price, consideration received, or use of proceeds.
The amended and restated articles of association were filed with the commercial registry of the Canton of Zurich, Switzerland, and are included as Exhibit 99.1. The report is incorporated by reference into specified Form F-3 registration statements, subject to later filings.
Key Facts for Investors to Verify
- Confirm that the filing relates to NLS Pharmaceutics Ltd.; the supplied request metadata identifies Newcelx Ltd.
- Review Exhibit 99.1 for the complete amended and restated articles of association.
- Verify the issuance price, total proceeds, transaction counterparties, and use of proceeds, which are not provided in the filing text.
- Assess the effect of the 3,891,469 newly issued shares on dilution, voting rights, and ownership percentages.
- Confirm the updated share count of 39,563,249 and share capital of CHF 791,264.98 against subsequent company filings.